Earlier this year, WHATNEXT partner site Patient Worthy shared an article about promising findings in a phase 3 trial for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The trial reported improved progression-free survival in the patients that participated.
Author Rose Duesterwald reports:
“The primary outcome from the Phase III NETTER-2 clinical trial as reported recently in Globe Newswire, was heralded as extending progression free survival from 8.5 months to 22.8.
The participants were newly diagnosed patients with rare advanced gastroenteropancreatic neuroendocrine tumors (NETS).”
Get the fully story here.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
gastroenteropancreatic neuroendocrine tumors GEP-NETs neuroendocrine tumors research treatment
Last modified: August 12, 2024
